The analysis of the six included studies indicated an overall non‐significant decrease in the lipid profiles (total cholesterol (TC), low‐density lipoprotein cholesterol (LDL), high‐density lipoprotein cholesterol (HDL), and triglyceride (TG)), and liver enzymes (aspartate transaminase (AST), alanine transaminase (ALT), and gamma‐glutamyltransferase (GGT)) of NAFLD patients who received CoQ10. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.